How Is Medtronic's Stock Performance Compared to Other Medical Devices Stocks?

Galway, Ireland-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. Valued at $134.7 billion by market cap, the company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and MDT perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical devices industry. MDT's global presence and wide product range, covering chronic diseases like diabetes, cardiovascular conditions, and neurological disorders, are its key strengths. With around half of sales coming from international markets, the company has a diverse geographic reach that helps mitigate economic risks, reducing its dependence on any one product or market.